Human Serum Albumin Domain I Fusion Protein for Antibody Conjugation.

Bioorthogonal labeling of antibodies enables the conjugation of compounds, such as small molecules or peptides, which expand targeting capacity or enhance cytotoxicity. Taking advantage of a cyclohexene sulfonamide compound that site-selectively labels Lys64 in human serum albumin (HSA), we demonstrate that domain I of HSA can be used as a fusion protein for the preparation of antibody conjugates. Trastuzumab fusions were expressed at the N-terminus of the light chain or the C-terminus of the heavy chain enabling conjugation to small molecules. Moreover, these conjugates retained HER2 binding and proved to be highly stable in human plasma. Antibody conjugation via HSA domain I fusion should therefore have broad utility for making serum-stable antibody conjugates, particularly for antibody-drug conjugates.

[1]  Christopher G. Parker,et al.  Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease. , 2012, ACS chemical biology.

[2]  Kai Johnsson,et al.  An engineered protein tag for multiprotein labeling in living cells. , 2008, Chemistry & biology.

[3]  C. Barbas,et al.  Site-selective labeling of a lysine residue in human serum albumin. , 2014, Angewandte Chemie.

[4]  Christina Peters,et al.  Antibody–drug conjugates as novel anti-cancer chemotherapeutics , 2015, Bioscience reports.

[5]  C. Barbas,et al.  Improving the Serum Stability of Site-Specific Antibody Conjugates with Sulfone Linkers , 2014, Bioconjugate chemistry.

[6]  Damon L. Meyer,et al.  Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.

[7]  T. Kaisho,et al.  Analysis of binding site for the novel small‐molecule TLR4 signal transduction inhibitor TAK‐242 and its therapeutic effect on mouse sepsis model , 2009, British journal of pharmacology.

[8]  Andrew Burnette,et al.  Monoclonal antibody therapeutics with up to five specificities , 2013, mAbs.

[9]  M. Francis,et al.  Regioselective labeling of antibodies through N-terminal transamination. , 2007, ACS chemical biology.

[10]  F. Theil,et al.  Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. , 2011, Bioconjugate chemistry.

[11]  Marjeta Urh,et al.  HaloTag: a novel protein labeling technology for cell imaging and protein analysis. , 2008, ACS chemical biology.

[12]  Paul Polakis,et al.  Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index , 2008, Nature Biotechnology.

[13]  M. Sliwkowski,et al.  Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates , 2012, Nature Biotechnology.

[14]  P. Dawson,et al.  Enhanced catalysis of oxime-based bioconjugations by substituted anilines. , 2014, Bioconjugate chemistry.

[15]  U. Brinkmann,et al.  Engineered hapten‐binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload delivery , 2016, Immunological reviews.

[16]  R. Fuller,et al.  Development of a small peptide tag for covalent labeling of proteins. , 2007, Bioconjugate chemistry.

[17]  P. Brick,et al.  Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites , 1998, Nature Structural Biology.

[18]  A. Wahl,et al.  Antibody conjugates with unnatural amino acids. , 2015, Molecular pharmaceutics.

[19]  P. Dawson,et al.  Rapid oxime and hydrazone ligations with aromatic aldehydes for biomolecular labeling. , 2008, Bioconjugate chemistry.

[20]  C. Bertozzi,et al.  Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development , 2014, Bioconjugate chemistry.

[21]  P. Burke,et al.  A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. , 2013, Bioconjugate chemistry.

[22]  M. Yamada,et al.  Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: synthesis and biological activity of alkyl 6-(N-substituted sulfamoyl)cyclohex-1-ene-1-carboxylate. , 2005, Journal of medicinal chemistry.

[23]  Paul Polakis,et al.  Site-specific antibody drug conjugates for cancer therapy , 2013, mAbs.

[24]  Rongsheng E. Wang,et al.  Antibody-drug conjugates for non-oncological indications , 2016, Expert opinion on biological therapy.

[25]  U. Brinkmann,et al.  Hapten-directed spontaneous disulfide shuffling: a universal technology for site-directed covalent coupling of payloads to antibodies , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  Benjamin W. Thuronyi,et al.  Identification of highly reactive sequences for PLP-mediated bioconjugation using a combinatorial peptide library. , 2010, Journal of the American Chemical Society.

[27]  A. Juillerat,et al.  Directed evolution of O6-alkylguanine-DNA alkyltransferase for efficient labeling of fusion proteins with small molecules in vivo. , 2003, Chemistry & biology.